Determinaciones de niveles de creatina y lípidos mediante espectroscopia por resonancia magnética en miocardio de pacientes con insuficiencia cardiaca no isquémica

Winter, José Luis; Castro, Pablo; Meneses, Luis; Chalhub, Mónica; Verdejo, Hugo; Greig, Douglas; Gabrielli, Luigi; Chiong, Mario; Concepción, Roberto; Mellado, Rosemerie; Hernandez, Claudia A; Uribe, Sergio; Lavandero, Sergio

doi:10.4067/s0034-98872010001300001

Cited by 3 publications

(1 citation statement)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, they found in humans a concurrent decrease in creatine transporter, which they concluded was the cause of the creatine decrease. Winter et al [51] found with magnetic resonance spectroscopy a decrease in total creatine in patients affected by cardiac failure not due to ischemia. Neubauer et al [52] used in vivo 31P-MR spectroscopy to investigate the phosphocreatine/ATP ratio in human volunteers and in heart failure patients.…”

Section: Decrease In Creatine In Heart Failurementioning

confidence: 99%

Role of Creatine in the Heart: Health and Disease

Balestrino

2021

Nutrients

View full text Add to dashboard Cite

Creatine is a key player in heart contraction and energy metabolism. Creatine supplementation (throughout the paper, only supplementation with creatine monohydrate will be reviewed, as this is by far the most used and best-known way of supplementing creatine) increases creatine content even in the normal heart, and it is generally safe. In heart failure, creatine and phosphocreatine decrease because of decreased expression of the creatine transporter, and because phosphocreatine degrades to prevent adenosine triphosphate (ATP) exhaustion. This causes decreased contractility reserve of the myocardium and correlates with left ventricular ejection fraction, and it is a predictor of mortality. Thus, there is a strong rationale to supplement with creatine the failing heart. Pending additional trials, creatine supplementation in heart failure may be useful given data showing its effectiveness (1) against specific parameters of heart failure, and (2) against the decrease in muscle strength and endurance of heart failure patients. In heart ischemia, the majority of trials used phosphocreatine, whose mechanism of action is mostly unrelated to changes in the ergogenic creatine-phosphocreatine system. Nevertheless, preliminary data with creatine supplementation are encouraging, and warrant additional studies. Prevention of cardiac toxicity of the chemotherapy compounds anthracyclines is a novel field where creatine supplementation may also be useful. Creatine effectiveness in this case may be because anthracyclines reduce expression of the creatine transporter, and because of the pleiotropic antioxidant properties of creatine. Moreover, creatine may also reduce concomitant muscle damage by anthracyclines.

show abstract

Section: Decrease In Creatine In Heart Failurementioning

confidence: 99%